Olsson, Petter http://orcid.org/0000-0002-3913-3914
Skröder, Carl
Ahlbeck, Lars
Hjalte, Frida
Welin, Karl-Olof
Westin, Ulla
Andersson, Morgan
Ahlström-Emanuelsson, Cecilia
Cardell, Lars-Olaf
Funding for this research was provided by:
Swedish Rhinological Research Alliance
ALK Nordic A/S
Karolinska Institute
Article History
Received: 2 December 2020
Accepted: 25 May 2021
First Online: 7 June 2021
Declarations
:
: Subjects gave their informed consent and the study protocol was approved by the local Ethical committee at Karolinska Institutet, Stockholm, Sweden (Dnr 2016/2158–31/2).
: Not applicable.
: PO is an employee of Novartis AB and a shareholder of Novartis AG. CS has no conflicts of interest to declare. LA has received honoraria as a speaker or adviser from AstraZeneca, Meda, Takeda, Teva, Boehinger Ingelheim, MSD, Sanofi and Novartis. FH CS has no conflicts of interest to declare. Karl-Olof Welin has no conflicts of interest to declare. Ulla Westin has no conflicts of interest to declare. Morgan Andersson has no conflicts of interest to declare. Cecilia Ahlström-Emanuelsson has no conflicts of interest to declare. Lars-Olaf Cardell has received unrestricted grants from ALK Nordic A/S.